A new paradigm for preventing and treating neurodegeneration

Acelot is a development stage biopharmaceutical company focused on therapies for neurodegenerative disorders.

A Unified Approach

We combine actively learning generative AI, in-house assays, and molecular dynamic simulations to unlock novel insights into targeting misfolded proteins where no crystal structures of the target exist.

Our Team

Katie Planey


Leader in building data-driven biotech companies

Lewis Whitehead

VP of Research, Computational Discovery

Computational medicinal chemist with expertise in small molecule drug discovery

Vidhu Mathur

Director of Research, Preclinical, PhD

Neurodegenerative preclinical research expert

Andrew Carr

Senior Scientist I, PhD

Expert in algorithms, machine learning, and database design

Marcela Kokes

Senior Scientist I, PhD

Expert in cell biology and mechanistic biology

Shruti Arya

Senior Scientist I, PhD

Expert in protein biophysics/biochemistry and molecular mechanisms of neurodegenerative diseases

Devi Supriya Korumilli

Research Associate

Experienced in next generation sequencing and Neuroscience enthusiast

Cody Aldaz

Data Scientist

Expert in theoretical chemistry and deep learning

Kevin Burk

Data Scientist, MS

Software and machine learning expert


Ambuj Singh

Founder & Board Member, Acelot; UCSB Professor, Department of Computer Science, Biomolecular Science and Engineering

David Bleakman

President, Drug Discovery Psychogenics; Former CSO, Eli Lilly Neuroscience; Former CSO, Redpin Therapeutics

Andrew Perlman

Co-founder & Managing Director, X37; Former EVP, Tularik; Former CEO, Innate Immune; Former Director of Clinical Development, Genentech

Mike Kavanaugh

CSO, Cytomx; Former CSO, Five Prime Therapeutics; Former VP, Novartis Vaccines & Diagnostics